Cargando…
Consensus Management of Gastrointestinal Events Associated with Delayed-Release Dimethyl Fumarate: A Delphi Study
INTRODUCTION: Delayed-release dimethyl fumarate (DMF, also known as gastro-resistant DMF) is indicated for the treatment of patients with relapsing multiple sclerosis. Gastrointestinal (GI) adverse events (AEs) occur with DMF therapy. METHODS: We used a Delphi process to reach consensus among North...
Autores principales: | Theodore Phillips, J., Erwin, April A., Agrella, Stephanie, Kremenchutzky, Marcelo, Kramer, John F., Darkes, Malcolm J. M., Kendter, Jonathan, Abourjaily, Heather, Rana, Jitesh, Fox, Robert J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4685868/ https://www.ncbi.nlm.nih.gov/pubmed/26525536 http://dx.doi.org/10.1007/s40120-015-0037-x |
Ejemplares similares
-
Characterizing absolute lymphocyte count profiles in dimethyl fumarate–treated patients with MS: Patient management considerations
por: Fox, Robert J., et al.
Publicado: (2016) -
Real-world use of dimethyl fumarate in patients with plaque psoriasis: a Delphi-based expert consensus
por: Burlando, Martina, et al.
Publicado: (2022) -
Nursing Management of Gastrointestinal Adverse Events Associated With Delayed-Release Dimethyl Fumarate: A Global Delphi Approach
por: Campbell, Trudy L., et al.
Publicado: (2020) -
Effect of dimethyl fumarate on lymphocytes in RRMS: Implications for clinical practice
por: Mehta, Devangi, et al.
Publicado: (2019) -
Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing–remitting multiple sclerosis (RRMS)
por: Gold, Ralf, et al.
Publicado: (2015)